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Background: Treatment with radium-223 has been shown to increase survival and to delay skeletal
events related to bone metastases of patients with metastatic Castration Resistant Prostate Cancer
(mCRPC). This treatment has also proved to be well tolerated, and hematological toxicity, in particular
anemia, represents the most represented adverse event.
Materials and methods: We evaluated the hematologic toxicity of Ra-223 treatment in a real-life
experience of 38 patients from two Italian cancer centers, with bone metastases from mCRPC. The
main endpoint of the study was the evaluation of the efficacy and tolerability of treatment with radium-
223, with greater reference to hematological toxicity (especially anemia) as the cause of interruption of
treatment, specifically in the elderly patient.
Results: From August 2016 to October 2017, a total of 38 consecutive nonselected patients, 20 of them
aged >75 years, with mCRPC symptomatic bone metastases, were enrolled for radium-223 at stan-
dard doses. Hematologic adverse events were recorded more frequently (72.4% with AE), and 36.8%
had anemia. The most frequent cause of treatment discontinuation due to AEs was anemia [8/10
patients (80%)], followed by thrombocytopenia (2 patients) and neutropenia (1 patient). Hematologic
AEs were more represented in elderly patients with greater disease burden and previously treated
with docetaxel.
Conclusions: Anemia is the most represented AE related to radium-223 treatment in elderly patients
with greater disease burden and previously treated with docetaxel, besides representing the main reason
for interruption of treatment. Correct patient selection, appropriate timing, and adequate supportive care
are elements that could facilitate successful treatment with radium-223, preventing premature inter-
ruption of the same. The results of this experience support the opportunity to propose treatment with
radium-223 mostly in patients in the earliest stages.
© 2019 APPS& KPS, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the most common cancer among adult men in
Western countries.1 Patients with hormone-refractory prostate
cancer frequently develop skeletal metastases. The mechanisms of
bonemetastases in prostate cancer patients include factors released
by tumor cells that stimulate both osteoclast and osteoblast activ-
ity.2,3 Bone metastases are clinically characterized by pain, spinalberto I” Hospital e RAO e
ed by Elsevier Korea LLC. This is acord compression, pathological fracture, and pancytopenia, which
represent themost skeletal-related events (SREs) that are capable of
modifying patient survival.4 Bisphosphonates,5 denosumab,6 and
radioisotope7 treatments are used for pain relief and the delay of
skeletal events. Radium-223 dichloride (radium-223) is a targeted
alpha emitter that selectively binds to areas of increased bone
turnover in bone metastases and emits high-energy alpha particles
of short range (<100 mm).8,9 The mechanism of action of this
radiopharmaceutical consists in selectively binding to areas of
increased bone turnover in and around metastases and emitting
energy. The high-energy alpha-particle radiation induces predomi-
nantly nonreparable DNA double-strand breaks that cause cytotoxicn open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Baseline clinical characteristics of patients treated with radium-223.
Characteristic Patients (38)
Age
Median (range), yr 74.02 (56e86)
<75 yr, no. (%) 18 (47.3)
75 yr, no. (%) 20 (52.6)




Extent of disease, no. (%)
<6 metastases 9 (23.6)
6e20 metastases 7 (25)
>20 metastases 22 (57.8)
Median basal biochemical values (range)
Hemoglobin, g/dL 12.6 (10.3e15.2)
Total alkaline phosphatase, U/liter 125.1 (58e255)
PSA, ng/dL 46.9 (0.17e419)




Any previous use of docetaxel, no. (%)
Yes 24 (63.2)
Also Abi/Enza no. (% of yes) 11 (45.8)
Also cabazitaxel no. (% of yes) 12 (50)
No 14 (36.8)
Only ADT (% of not) 8 (57.2)
ADT þ Abi/Enza (% of not) 6 (42.8)




Current use of bisphosphonates, no. (%)
Yes 8 (21.05)
Current use of denosumab, no. (%)
Yes 3 (7.8)
PSA, prostate-specific antigen.
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marrow is reduced because of the short range (from 40 to 100 ìm) of
energy emitted.11
In Phase 2 and Phase 3 studies, radium-223 showed a favorable
safety profile with low myelotoxicity.11,12
Radium-223 is approved in the USA13 and Europe14 for men
with mCRPC with symptomatic bone metastases and no visceral
metastatic disease.
In Phase 3, randomized, double blind, placebo-controlled
ALSYMPCA trial,15 radium-223 has shown an advantage in me-
dian survival versus placebo (14.9 months vs. 11.3 months). The
treatment also prolonged the time to the first symptomatic skeletal
event (median, 15.6 months vs. 9.8 months). In ALSYMPCA trial,
radium-223 was well tolerated.15 Hematologic AEs were the most
common, and in particular, all-grade anemia was recorded in
31% and Grade 3e5 in 13% of patients.
Data from 3-year safety follow-up analysis from ALSYMPCA trial
showed that radium-223 continued to be well tolerated, with a low
incidence of myelosuppression, long-term preservation of he-
matopoietic function, and no new safety signals.16
The efficacy and tolerability data of a real-life experience of
patients treated with radium-223 will be illustrated in the
following.
2. Subjects, materials, and methods
2.1. Patients
We reported the cases of 38 consecutive nonselected patients
with mCRPC symptomatic bone metastases treated in two Italian
cancer centers from August 2016 to October 2017. All patients
had the same characteristics as patients enrolled in the
ALSYMPCA study,15 i.e., patients symptomatic, progressive, and
bone-predominant mCRPC with >2 bone metastases on imaging
with no lung, liver, or brain metastases. Lymph node metastases
were allowed. Symptomatic was defined as regular use of any
analgesic medication for cancer-related bone pain (level 1;
World Health Organization ladder for cancer pain). All treated
patients were symptomatic for bone pain, and 15.8% of them
were highly symptomatic. Progressive was defined as the
appearance of new bone lesions or two subsequent increases in
serum prostate-specific antigen (PSA) above the previous refer-
ence value.
The mean age of the patients in the study was 74 years; 20 of
these were old patients aged 75 years. All patients had histolog-
ically confirmed, progressive castration-resistant prostate cancer
with two or more bone metastases detected on skeletal scintig-
raphy and no known visceral metastases, and 57.8% of patients had
>20 metastatic lesions. Castration-resistant disease was defined as
a serum testosterone level of 50 ng/dL or lower in progression after
androgen deprivation therapy (ADT) treatment. More than half of
the patients (57.8%) had an Eastern Cooperative Oncology Group
(ECOG) performance status  1, and 42.2% of them had perfor-
mance status  2.
Twenty-two patients (57.9%) had cardiovascular comorbidities
(hypertension, dilated cardiomyopathy, and arrhythmias), and
almost all (97.3%) had good renal and hepatic function.
Of all patients who began treatment with radium-223, 24
(63.2%) had previously been treated with docetaxel (11 also with
abiraterone or enzalutamide and 12 also with cabazitaxel), and 14
patients had not previously been treated with docetaxel (6 had
received only abiraterone or enzalutamide and 8 only ADT). Eight
patients had undergone previous external-beam radiation therapy,
four patients on the prostatic loggia, and six patients also received
radiotherapy on the bone. Eight patients treated with radium-223also underwent concomitant treatment with bisphosphonates, and
three patients with denosumab (Table 1). No other treatment, with
the exception of bisphosphonates or denosumab, had been tried by
all patients.
2.2. Study design and treatment
We performed a retrospective observational study in real life of
38 patients treated with radium-223 in two Italian cancer centers.
All treated patients were able to perform radium-223
treatment according to the indications of the drug, and they per-
formed the standard dose of 50 kBq per kg of body weight,
administered at 4-week intervals for six injections.
The treatment period was the time from the first radium-223
dose to 30 days after the last dose. Visits were made for each cy-
cle (i.e., every 4 weeks 67 days) for treatment and evaluation of
ECOG performance status, clinical laboratory tests, SSEs, and AEs.
The clinical data of each patient were identified, in particular the
blood values (Hb, PLT, and granulocyte counts), PSA, and alkaline
phosphatase values in baseline and the detection of pain in baseline
and the possible response antalgic, the various treatment-related
toxicities in different degrees of expression in subsequent
evaluations.
2.3. Outcomes
Primary outcomes of our study were acute and long-term safety
of radium-223, with greater reference to hematological toxicity
(especially anemia) as the cause of interruption of treatment, spe-
cifically in the elderly patient. The efficacy of treatment was also
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rate, and the response to the total alkaline phosphatase and PSA
level.
Radiographic response rate was evaluated with the use of either
computed tomography or 11C-Choline positron emission tomogra-
phy/computed tomography (PET/CT) and with the use of bone
scanning. Imaging was performed at the time of screening and at
the end of the treatment. Radiologists at a central location who
were unaware of the study group assignments determinedwhether
there was progressive disease on the basis of Response Evaluation
Criteria in Solid Tumors, version 1.1, for soft tissue or on the basis of
criteria adapted from the Prostate Cancer Clinical Trials Working
Group 217 for osseous disease.
Safety was assessed on the basis of AEs, hematologic values,
clinical laboratory variables, and findings on electrocardiography
and physical examination. All AEs that occurred after the start of
treatment and within 12 weeks after the last injection of radium-
223 were reported and evaluated.
AEs were graded according to the CommonTerminology Criteria
for Adverse Events, version 3.0.18
3. Results
Overall, 20 of 38 patients (52.6%) had received all six in-
jections of the treatment radium-223. The median number of
injections was 4.1 in patients aged 75 years and 4.6 in patients
aged <75 years.
3.1. Safety
The number of patients with AEs related to treatment with
radium-223 was quite remarkable: 29 of 38 patients (76.3%) had AE
of any grade, 28.9% (11 pts) had Grade 3 or 4 AE, and 10 patients
(26.3%) stopped the treatment because of AEs. Eight patients did
not complete treatment for other causes (3 for visceral progression
during treatment and 5 died).
Hematologic and nonhematologic AEs that occurred are shown
in Table 2.
Hematologic AEs were recorded more frequently [21 of 29 pa-
tients (72.4%) with AE]: 14 of all patients (36.8%) had anemia, 8 of
which were severe anemia (21.05%), neutropenia was reported in 3
patients (7.8%), Grade 3 febrile neutropenia in one patient (<3%),
and thrombocytopenia in four patients (10.5%). The most common
nonhematological AEs were fatigue (15.7%) and diarrhea (18.4%),Table 2
Adverse events recorded and broken down by age (>or < 75 years) and in relation to pr
Adverse events N (%) Patients t
Previous docetaxel use (N ¼ 24)
Age > 75 yr (N ¼ 12) Age < 75 yr (N
All Grade G3e5 All grade
Hematological adverse events
Anemia 8 (21.05%) 5 (13.1%) 4 (10.5%)
Neutropenia 2 (5.2%) 1 (2.6%) 0 (0%)
Thrombocytopenia 3 (7.8%) 1 (2.6%) 0 (0%)
Nonhematological adverse events
Constipation 0 (0%) 0 (0%) 0 (0%)
Diarrhea 3 (7.8%) 1 (2.6%) 1 (2.6%)
Nausea/Vomiting 1 (2.6%) 0 (0%) 1 (2.6%)
Fatigue 2 (2.6%) 0 (0%) 1 (2.6%)
Anorexia 0 (0%) 0 (0%) 0 (0%)
Weight decreased 1 (2.6%) 0 (0%) 0 (0%)
Fever 2 (2.6%) 0 (0%) 1 (2.6%)
Peripheral edema 0 (0%) 0 (0%) 0 (0%)two of Grade > 2, none of which resulted in discontinuation of
treatment.
The most frequent cause of treatment discontinuation due to
AEs was anemia [8/10 patients (80%)], followed by thrombocyto-
penia (2 patients) and neutropenia (1 patient).
3.2. Exploratory efficacy
At the interim analysis, at 16 months from the beginning of the
study, of the 38 patients enrolled, 33 of them (86.8%) are still alive,
and five are dead from causes related to the tumor.
The responses obtained in the 20 patients who completed the
treatment (carried out six injections) were verified: 11 of 20 (55%)
patients had a metabolic (evaluated with 11C-Choline PET/CT) and
clinical (pain response) partial response, 2 patients (10%) had a
disease stability with objective response rate 65%, and 7 of 20 (35%)
patients had an iconographic disease progression. Responses to
alkaline phosphatase and PSA levels were also assessed: 15 of 38
patients (39.4%) had a reduction > 30% in the levels of alkaline
phosphatase during treatment, 11 of whom had taken 6 injections
of Ra-223; 29 patients had PSA levels increased during treatment,
and only 9 patients (23.6%) had a PSA response > 30%, 6 of whom
had completed treatment.
4. Discussion
Radium-23 treatment is an excellent alternative for patients
with mCRPC and bone metastases, as described by numerous
literature data and the increasing experience in real life. In addition
to an effective treatment that is able to offer a survival advantage
and a reduction of skeletal events related to bone metastases,15
radium-223 is also a well-tolerated treatment, and related toxic-
ities are far from those recorded with antiblastic treatments.
In the ALSYMPCA study, the number of patients who had AEs
was consistently lower in the radium-223 group than in the pla-
cebo group for all AEs [558 of 600 patients (93%) vs. 290 of 301
patients (96%)], Grade 3 or 4 AEs [339 patients (56%) vs. 188 pa-
tients (62%)], serious AEs [281 patients (47%) vs.181 patients (60%)],
and study drug discontinuation because of AEs [99 patients (16%)
vs. 62 patients (21%)].15 Themost frequent nonhematological AEs in
the radium-223 patient group were nausea (36%), fatigue (26%),
diarrhea (25%), and constipation (18%), although with frequency
overlapping that of the control group, with the exception of diar-
rhea (25% vs. 15%). The rates of myelosuppression recorded in theevious treatment with docetaxel (yes or not).
reated with radium-223 (N ¼ 38)
No previous docetaxel use (N ¼ 14)
¼ 12) Age > 75 yr (N ¼ 8) Age < 75 yr (N ¼ 6)
G3e5 All grade G3e5 All grade G3e5
2 (5.2%) 1 (2.6%) 1 (2.6%) 1 (2.6%) 0 (0%)
0 (0%) 1 (2.6%) 1 (2.6%) 0 (0%) 0 (0%)
0 (0%) 1 (2.6%) 0 (0%) 0 (0%) 0 (0%)
0 (0%) 1 (2.6%) 0 (0%) 0 (0%) 0 (0%)
0 (0%) 2 (5.2%) 1 (2.6%) 1 (2.6%) 0 (0%)
0 (0%) 1 (2.6%) 0 (0%) 1 (2.6%) 0 (0%)
0 (0%) 2 (2.6%) 0 (0%) 1 (2.6%) 0 (0%)
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
0 (0%) 1 (2.6%) 0 (0%) 1 (2.6%) 0 (0%)
0 (0%) 0 (0%) 0 (0%) 1 (2.6%) 0 (0%)
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thrombocytopenia, 12%; and neutropenia, 5%.15
In a recent analysis of patients included in the ALSYMPCA study,
the AEs that have occurred and persisted for a long time after the
discontinuation of treatment, including acute myeloid leukemia,
myelodysplastic syndrome, and second tumors were examined. Pa-
tients (405 radium-223 and 167 placebo) entered long-term safety
follow-up starting 12 week after the last study drug injection to
3 years from thefirst injection.Myelosuppression incidencewas low.
Grade 3/4 hematologic AEs in radium-223 and placebo groups were
anemia (13% vs.13%), neutropenia (2% vs.1%), and thrombocytopenia
(7% vs. 2%). Long-term follow-up showednoacutemyeloid leukemia,
myelodysplastic syndrome, or new primary bone cancer; secondary
nonetreatment-related malignancies occurred in four radium-223
and three placebo patients. One radium-223 patient had aplastic
anemia 16 mo after the last injection.16
Our data, in reference to the hematological toxicity, are in line
with what was recorded in the ALSYMPCA study (anemia 36% vs.
31%, thrombocytopenia 10.5% vs. 12%, neutropenia 7.8% vs. 5%),
although these toxicities, when they are of a high degree, have
more determined the suspension of treatment (10/38: 26.3%). In
detail, the discontinuity due to hematological toxicity occurred in 2
of 18 patients (11.1%) in the group aged <75 years and in 8 of 20
(40%) in the group aged  75 years. Furthermore, between the
patients aged 75 years, 3 deaths occurred during treatment,
although no correlation with the treatment was demonstrated. In
addition, the 8 patients aged 75 years who discontinued the
treatment for hematological toxicity (6 for anemia) had marked
bone compromise with >20 metastatic lesions, 7 of 8 patients
(87,5%) had received previous chemotherapy treatments and one of
these was 85 years old at the start of treatment. Older age, previous
myelotoxic treatments, and a large extent of disease could therefore
be predictors of bone marrow toxicity.
The hematological toxicity related to the treatment with
radium-223 is comparable to that registered with the new hor-
monal treatments, abiraterone and enzalutamide19e21 and signifi-
cantly lower than that recorded with cytotoxic chemotherapies
(docetaxel and cabazitaxel), in which myelosuppression represents
the most frequent toxicity.22,23 Moreover, radium-223 is distin-
guished from beta-emitting radiopharmaceuticals, which are
associated with significant hematologic events (mainly leukopenia
and thrombocytopenia).24
A phase II, open-label, single-arm, multicenter U.S. expanded
access program (EAP),25 recently published, enrolled 184 patients
with the same characteristics of the patients of the ALSYMPCA
study who received radium-223 at standard doses for up to 6 cy-
cles. Additional analyses were done by prior or concomitant abir-
aterone or enzalutamide use. Concurrent abiraterone was
administered to 25 of 184 (14%) patients, and concurrent enzalu-
tamide to 15 of 184 (8%) patients. Radium-223 concurrently
administered with abiraterone or enzalutamide was well tolerated.
The most frequent Grade 3e4 adverse events were anemia (abir-
aterone 16%, enzalutamide 13%), thrombocytopenia (abiraterone
4%, enzalutamide 0%), and back pain (abiraterone 0%, enzalutamide
13%). The results of this study demonstrate that concomitant use of
radium-223 and androgenic receptor (AR)-target agents does not
change the toxicity profile of the treatment.
Despite this tolerability profile, our data showed a greater
discontinuity in treatment, especially in elderly patients with
greater disease burden and previously treated with myelotoxic
drugs.
Few literature data concern patients aged >75 years, but other
authors suggest that some factors such as extensive bone disease
and previous treatment with docetaxel may be predictive of
myelotoxicity.A high rate of anemia has been reported in patients with CRPC
and bonemetastases,26,27 and therefore, the burden of bone disease
could in itself represent a predictor of hematological toxicity. In
ALSYMPCA study, anemia was the most common hematologic
toxicity: current prescribing information recommends that hemo-
globin be  10 g/dL before the first radium-223 administration.
Ongoing protocols allow hemoglobin 8 g/dL (with transfusions).
In a post hoc analysis of data from ALSYMPCA study,28 the effi-
cacy and toxicity data of patients previously undergoing treatment
with docetaxel were compared with those of patients who had not
undergone this treatment. Radium-223 prolonged median overall
survival compared with placebo, irrespective of previous docetaxel
use (previous docetaxel use, hazard ratio 0.70, 95% confidence in-
terval 0.56e0.88; P¼ 0.002; no previous docetaxel use, hazard ratio
0.69, confidence interval 0.52e0.92; P ¼ 0.01). The benefit of
radium-223 compared with placebo was seen in both docetaxel
subgroups for most main secondary efficacy endpoints; risk for
time to symptomatic skeletal event was reduced with radium-223
versus placebo in patients with previous docetaxel use, but the
difference was not meant in those with no previous docetaxel use.
Patients who had previously been treated with docetaxel had a
higher incidence of Grade 3e4 thrombocytopenia with radium-223
than with placebo (9% vs. 3%), whereas the incidence was similar
between treatment groups among patients with no previous
docetaxel use (3% vs. 1%). The incidences of Grade 3e4 anemia and
neutropenia were similar between the radium-223 and placebo
groups within both docetaxel subgroups.28
A multivariate analysis of data from ALSYMPCA patients29
identified baseline factors that may increase hematologic toxicity
risk with radium-223. Authors suggest that the extent of disease
(6e20 vs. < 6 bone metastases; odds ratio ¼ 2.76; P ¼ 0.022) and
degree of PSA elevation (odds ratio ¼ 1.65; P ¼ 0.006) were pre-
dictive of Grade 2-4 anemia; prior docetaxel treatment with asso-
ciated decreased hemoglobin and platelets was predictive of Grade
2-4 thrombocytopenia. There were no significant associations be-
tween hematologic toxicities and number of radium-223 injections
received.29
Considering these results and the data of our patients, whose
hematological toxicity from radium-223 was more represented in
elderly patients previously treated with Docetaxel, in the choice of
treatment, it could be possible to select patients with earlier bone
disease and who are chemo naïve.
In this regard, a subgroup analysis of the ALSYMPCA
study tested the results in terms of efficacy and tolerability in pa-
tients who had not undergone previous chemotherapy [30] but
who had subsequently undergone treatment with antiblastic
treatment (70%with docetaxel, 16% with mitoxantrone). In radium-
223 and placebo patients receiving subsequent chemotherapy,
median hematologic values (hemoglobin, neutrophils, and plate-
lets) remained nearly constant up to 18 months after the start of
chemotherapy. A low percentage of patients in both groups had
Grades 3e4 hematologic values (<10%). Median overall survivals
from the start of chemotherapy were 16.0 and 15.8 months after
radium-223 and placebo, respectively.30
The results of our study showed that patients treated with
radium-223 andwho had never undergone previous chemotherapy
(36.8%) had a much lower hematological toxicity than those who
had previously been treated with chemotherapy [4/14 (28.5%) vs.
16/24 (66.6%)], most of whom [3/4 (75%)] were elderly. It may
therefore be appropriate to anticipate the treatment with radium-
223, postponing chemotherapy, to guarantee the same results with
a better toxicity profile. Finally, we must consider that hematologic
AEs are also easily managed if treated early with prophylactic or
curative use of granulocyte and erythrocyte growth factors and
transfusions of red blood cells/platelets. Correct patient selection,
R.P. Costa et al. / Hematologic toxicity of radium-223 in elderly patients 29appropriate timing, and adequate supportive care are elements that
could facilitate successful treatment, preventing premature inter-
ruption of the same.
5. Conclusion
Radium-223 represents an important advance in the treatment
of m-CRPC. Radium-223 offers a substantial improvement in the
overall survival with a highly favorable safety profile.
Hematological toxicity, especially anemia, is the most common
AE in patients treated with radium-223.
The results of our experience in real life, although with small
numbers, probably unrepresentative of the general population,
have shown that anemia is the most represented AE in elderly
patients with greater disease burden and previously treated with
docetaxel, besides representing the main reason for interruption of
treatment.
This experience supports the opportunity to propose treatment
with radium-223 in patients with more indolent disease and in the
earliest stages.
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